Maureen Newman,  —

Maureen Newman is a senior Science and Research writer for Cystic Fibrosis News Today. Maureen is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.

Articles by Maureen Newman

Ataluren Treatment Benefits Some nmCF Patients in Phase 3 Trial from PTC Therapeutics

PTC Therapeutics, Inc. announced unexpected, yet encouraging results of their product ataluren. The biopharmaceutical company focuses on developing small-molecule drugs that target post-transcriptional control processes to alter protein production. Ataluren is PTC’s investigational new drug designed to restore protein function in cystic fibrosis patients with a nonsense mutation (nmCF)…

PUR0400 Drug Formulation For Cystic Fibrosis (CF), non-CF Bronchiectasis Shows Promise In Recent Trial

Lexington, Massachusetts-based Pulmatrix made an impact at the 2014 Respiratory Drug Delivery Conference being held in Fajardo, Puerto Rico. A poster from the biotechnology company presented data related to PUR0400 (fluoroquinilone Levofloxac), a preclinical drug candidate formulated using Pulmatrix’s proprietary iSPERSE™ dry powder technology. PUR0400 is a drug formulation that…